Cost-Effectiveness of Posaconazole Compared with Standard Azole Therapy for Prevention of Invasive Fungal Infections in Patients at High Risk in Switzerland

Abstract

Given the conditions of the Swiss setting, posaconazole can be considered a cost-effective early treatment strategy that increases survival in patients at risk for IFI and may have a substantial benefit for the economic burden of IFI.